![Gustav von Schulthess](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Matthias Staehelin | M | - |
Nuclidium AG
![]() Nuclidium AG Miscellaneous Commercial ServicesCommercial Services Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway. | - |
Leila Jaafar-Thiel | M | - |
Nuclidium AG
![]() Nuclidium AG Miscellaneous Commercial ServicesCommercial Services Nuclidium AG is a private company located in Switzerland that is revolutionizing precision oncology by developing copper-based radiopharmaceuticals for targeted cancer treatment and diagnosis. The Swiss company's product portfolio utilizes the unique properties of copper to achieve improved safety and efficacy with advantageous economics for hospitals and patients. The company overcomes supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. Nuclidium's diverse and interdisciplinary team is focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients. The company's flexible CutraCeTM platform combines copper radiometals with highly specific cancer-targeting molecules to rapidly develop novel diagnostic and therapeutic programs. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks their development pathway. | 7 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 2 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gustav von Schulthess
- Personal Network